ImmunityBio (NASDAQ:IBRX) PT Lowered to $10.00 at Piper Sandler

ImmunityBio (NASDAQ:IBRX – Get Rating) had its target price trimmed by Piper Sandler from $20.00 to $10.00 in a research report sent to investors on Friday morning, The Fly reports.

Separately, Zacks Investment Research lowered shares of ImmunityBio from a hold rating to a sell rating in a research note on Tuesday, May 3rd.

NASDAQ IBRX opened at $3.92 on Friday. ImmunityBio has a 1 year low of $2.60 and a 1 year high of $18.14. The company has a fifty day moving average price of $4.56 and a 200-day moving average price of $5.71.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Point72 Hong Kong Ltd boosted its holdings in shares of ImmunityBio by 2,136.0% in the 1st quarter. Point72 Hong Kong Ltd now owns 6,149 shares of the company’s stock worth $34,000 after buying an additional 5,874 shares during the last quarter. Itau Unibanco Holding S.A. boosted its holdings in shares of ImmunityBio by 95.4% in the 4th quarter. Itau Unibanco Holding S.A. now owns 7,943 shares of the company’s stock worth $51,000 after buying an additional 3,878 shares during the last quarter. Sigma Planning Corp purchased a new position in shares of ImmunityBio in the 1st quarter worth about $59,000. Toroso Investments LLC purchased a new position in shares of ImmunityBio in the 1st quarter worth about $63,000. Finally, Landscape Capital Management L.L.C. purchased a new position in shares of ImmunityBio in the 4th quarter worth about $71,000. Hedge funds and other institutional investors own 8.67% of the company’s stock.

About ImmunityBio (Get Rating)

ImmunityBio, Inc, a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems.

See Also